Journal of the American Society of Nephrology, Vol 5, 1492-1497, Copyright © 1995 by American Society of Nephrology

REGULAR ARTICLES

Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats

T Nakamura, T Takahashi, M Fukui, I Ebihara, S Osada, Y Tomino and H Koide
Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan.

This study was designed to assess whether the glomerular expression of mRNA for extracellular matrix (ECM) components including alpha 1 (I), alpha 1 (III), and alpha 1 (IV) collagen chains, laminin B1 and B2 chains, metalloproteinases (MMP), and tissue inhibitor of metalloproteinases (TIMP) is affected by enalapril in 12- and 24-wk-old rat after streptozotocin injection. Animals were divided into three groups; untreated diabetic rats, enalapril-treated diabetic rats, and control rats. Enalapril treatment was continued for 24 wk. Enalapril reduced both creatinine clearance (P < 0.01) and urinary protein excretion (P < 0.01) in diabetic rats. In diabetic rats, mRNA levels for alpha 1 (IV) collagen chain, laminin B1 and B2 chains, and alpha 1(I) and alpha 1(III) collagen chains increased significantly at 24 wk compared with those in controls [alpha 1(IV): 3.8-fold (P < 0.01); laminin B1: 6.2-fold (P < 0.01); laminin B2:5.4-fold (P < 0.01), alpha 1(i): 4.8-fold (P < 0.01) and alpha 1(III): 3.8-fold (P < 0.01)]. At 24 wk, mRNA levels for MMP-1 and MMP-3 fell to 40% (P < 0.01) and 20% (P < 0.01), respectively, in the glomeruli of diabetic rats compared with levels in controls. In contrast, mRNA levels for TIMP-1 and TIMP-2 increased significantly at 24 wk after streptozotocin injection (TIMP- 1: 8.0-fold (P < 0.01) and TIMP-2: 6.4-fold (P < 0.01)).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C.-C. Wei, S.-L. Zhang, Y.-W. Chen, D.-F. Guo, J. R. Ingelfinger, K. Bomsztyk, and J. S. D. Chan Heterogeneous Nuclear Ribonucleoprotein K Modulates Angiotensinogen Gene Expression in Kidney Cells J. Biol. Chem., September 1, 2006; 281(35): 25344 - 25355. [Abstract] [Full Text] [PDF]

				H. Koppel, M. Christ, B. A. Yard, P. C. Bar, F. J. van der Woude, and M. Wehling Nongenomic Effects of Aldosterone on Human Renal Cells J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1297 - 1302. [Abstract] [Full Text] [PDF]

				J. H. Horstrup, M. Gehrmann, B. Schneider, A. Ploger, P. Froese, T. Schirop, D. Kampf, U. Frei, R. Neumann, and K.-U. Eckardt Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1005 - 1013. [Abstract] [Full Text] [PDF]

				D. J. CORDONNIER, N. PINEL, C. BARRO, C. MAYNARD, P. ZAOUI, S. HALIMI, B. H. DE LIGNY, Y. REZNIC, D. SIMON, and R. W. BILOUS Expansion of Cortical Interstitium Is Limited by Converting Enzyme Inhibition in Type 2 Diabetic Patients with Glomerulosclerosis J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1253 - 1263. [Abstract] [Full Text]

				J. J. Morrissey and S. Klahr Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis Am J Physiol Renal Physiol, January 1, 1999; 276(1): F39 - F45. [Abstract] [Full Text] [PDF]

				D. Chansel, S. Czekalski, S. Vandermeersch, E. Ruffet, M.-C. Fournie-Zaluski, and R. Ardaillou Characterization of angiotensin IV-degrading enzymes and receptors on rat mesangial cells Am J Physiol Renal Physiol, October 1, 1998; 275(4): F535 - F542. [Abstract] [Full Text] [PDF]

				G.N. Jyothirmayi, B.J. Soni, M. Masurekar, M. Lyons, and T.J. Regan Effects of Metformin on Collagen Glycation and Diastolic Dysfunction in Diabetic Myocardium Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(4): 319 - 326. [Abstract] [PDF]

				S. Nag and D. W. Kilty Cerebrovascular Changes in Chronic Hypertension : Protective Effects of Enalapril in Rats Stroke, May 1, 1997; 28(5): 1028 - 1034. [Abstract] [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673